GSK 2033
|
|
|
- CAS号:
- 1221277-90-2
- 英文名:
- GSK 2033
- 英文别名:
- GSK 2033;LXR antagonist 2033;GSK2033 >=98% (HPLC);Liver X receptor,Inhibitor,GSK 2033,inhibit,LXR,GSK2033,GSK-2033;2,4,6-Trimethyl-N-[[3'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]methyl]-N-[[5-(trifluoromethyl)-2-furanyl]methyl]benzenesulfonamide;Benzenesulfonamide, 2,4,6-trimethyl-N-[[3'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]methyl]-N-[[5-(trifluoromethyl)-2-furanyl]methyl]-
- 中文名:
- GSK 2033
- 中文别名:
- 化合物GSK2033;GSK2033,LXR拮抗剂
- CBNumber:
- CB93146298
- 分子式:
- C29H28F3NO5S2
- 分子量:
- 591.66
- MOL File:
- 1221277-90-2.mol
|
|
|
GSK 2033化学性质
-
储存条件:
-
2-8°C
-
|
-
溶解度:
-
DMF:5.0(Max Conc. mg/mL);8.45(Max Conc. mM)
DMSO:17.46(Max Conc. mg/mL);29.51(Max Conc. mM)-
|
-
形态:
-
powder
-
|
-
颜色:
-
white to beige
-
|
GSK 2033性质、用途与生产工艺
GSK2033 是一种 LXR 拮抗剂，对于 LXRα 和 LXRβ 的 pIC50 值分别为 7 和 7.4。
pIC50: 7 (LXRα), 7.4 (LXRβ)
GSK2033 is a LXR antagonist with pIC
50
s of 7 and 7.4 for LXRα or LXRβ, respectively. GSK2033 dose-dependently suppresses basal transcription in full-length LXRα or full-length LXRβ cotransfection assays with IC
50
s of 17 nM and 9 nM, respectively. GSK2033 also effectively suppresses the transcription of an
ABCA1
driven luciferase reporter dose-dependently displaying IC
50
s of 52 nM for LXRα and 10 nM for LXRβ. GSK2033 also suppresses the expression of both of fatty acid synthase (
FASN
) and
SREBP1
.
One month treatment of GSK2033 does not have significant effects on hepatic triglyceride levels. Plasma triglyceride levels are also unaffected by treatment with GSK2033.
GSK 2033
上下游产品信息
上游原料
下游产品
| 更新日期 | 产品编号 | 产品名称 | CAS编号 | 包装 | 价格 |
|---|
| 2024/04/30 | HY-108688 | GSK2033 | | 1 mg | 457元 |
| 2024/04/30 | HY-108688 | 1221277-90-2
GSK2033 | 1221277-90-2 | 5mg | 1100元 |
1221277-90-2, GSK 2033 相关搜索:
- 合成有机化合物配体
- C29H28F3NO5S2
- GSK2033,LXR拮抗剂
- 化合物GSK2033
- 1221277-90-2
- Liver X receptor,Inhibitor,GSK 2033,inhibit,LXR,GSK2033,GSK-2033
- GSK2033 >=98% (HPLC)
- Benzenesulfonamide, 2,4,6-trimethyl-N-[[3'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]methyl]-N-[[5-(trifluoromethyl)-2-furanyl]methyl]-
- 2,4,6-Trimethyl-N-[[3'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]methyl]-N-[[5-(trifluoromethyl)-2-furanyl]methyl]benzenesulfonamide
- LXR antagonist 2033
- GSK 2033